Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol's Glucophage (metformin) antihyperglycemic cost of therapy will be about $365 per year.

Executive Summary

BRISTOL GLUCOPHAGE LAUNCHING AT AVERAGE ANNUAL COST OF OVER $365, Bristol-Myers Squibb said during a May 4 teleconference announcing the launch of Glucophage (metformin) for Type II non-insulin dependent diabetes. The price of Glucophage will range from $296 to $767 per year at the maintenance doses of 1,000 mg to 2,550 mg per day. BMS said that the average patient would pay just over $1 per day.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS026149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel